Advertisement
Advertisement
TNXP
Tonix Pharmaceuticals Holding Corp.
12.44
USDSponsored
-0.56
-4.28%
Apr 10, 16:00 UTC -4
Closed
After-Market
12.64
+0.20
+1.62%
TNXP Earnings Reports
Positive Surprise Ratio
TNXP beat 21 of 41 last estimates.
51%
Next Report
Date of Next Report
May 11, 2026
Estimate for Q1 26 (Revenue/ EPS)
$10.27M
/-$2.81
Implied change from Q4 25 (Revenue/ EPS)
+90.50%
/-29.40%
Implied change from Q1 25 (Revenue/ EPS)
+322.73%
/-1.06%
Tonix Pharmaceuticals Holding Corp. earnings per share and revenue
On Mar 12, 2026, TNXP reported earnings of -3.98 USD per share (EPS) for Q4 25, missing the estimate of -3.25 USD, resulting in a -22.32% surprise. Revenue reached 5.39 million, compared to an expected 2.94 million, with a 83.27% difference. The market reacted with a -1.27% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 3 analysts forecast an EPS of -2.81 USD, with revenue projected to reach 10.27 million USD, implying an decrease of -29.40% EPS, and increase of 90.50% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AleAnna, Inc. Class A Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-Actual
$0.00
Surprise
-
Lexeo Therapeutics, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.32
Actual
-$0.27
Surprise
+15.84%
Unicycive Therapeutics, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.48
Actual
-$0.81
Surprise
-69.64%
Cardiol Therapeutics Inc. Class A Common Shares
Report Date
Apr 01, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.07
Surprise
+14.22%
Galectin Therapeutics Inc.
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.10
Actual
-$0.08
Surprise
+21.57%
Centessa Pharmaceuticals plc - ADR
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.38
Actual
-$0.48
Surprise
-23.58%
Actinium Pharmaceuticals, Inc
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.20
Surprise
-5.04%
Scienture Holdings, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.28
Actual
-$0.11
Surprise
+61.48%
Jupiter Neurosciences, Inc. Common Stock
Report Date
Apr 01, 2026 For Q4 25
Estimate
-$0.07
Actual
-$0.06
Surprise
+6.16%
60 Degrees Pharmaceuticals, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$2.32
Actual
-$2.34
Surprise
-0.62%
FAQ
What were Tonix Pharmaceuticals Holding Corp.'s earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Tonix Pharmaceuticals Holding Corp. reported EPS of -$3.98, missing estimates by -22.32%, and revenue of $5.39M, 83.27% above expectations.
How did the market react to Tonix Pharmaceuticals Holding Corp.'s Q4 2025 earnings?
The stock price moved down -1.27%, changed from $13.41 before the earnings release to $13.24 the day after.
When is Tonix Pharmaceuticals Holding Corp. expected to report next?
The next earning report is scheduled for May 11, 2026.
What are the forecasts for Tonix Pharmaceuticals Holding Corp.'s next earnings report?
Based on 3
analysts, Tonix Pharmaceuticals Holding Corp. is expected to report EPS of -$2.81 and revenue of $10.27M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement